Research programme: Helicobacter pylori infection therapies - AstraZeneca
Latest Information Update: 04 Nov 2017
At a glance
- Originator AstraZeneca
- Class Pyrazoles; Small molecules
- Mechanism of Action Glutamate racemase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Helicobacter infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Helicobacter-infections in USA (PO)
- 03 Sep 2010 Preclinical development is ongoing in USA
- 20 Aug 2009 Preclinical pharmacokinetics data presented at the 238th American Chemical Society National Meeting (238th-ACS-2009)